Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Chemotherapeutic and Targeted Strategies for Locally Advanced and Metastatic Esophageal Cancer

Chemotherapeutic and Targeted Strategies for Locally Advanced and Metastatic Esophageal Cancer STATE OF THE ART: CONCISE REVIEW Chemotherapeutic and Targeted Strategies for Locally  Advanced and Metastatic Esophageal Cancer Patrick M. Forde, MD and Ronan J. Kelly, MD, MBA highest incidence of esophageal cancer is in Asia and eastern Introduction: Esophageal cancer represents a major health care and southern Africa. In some areas of China, reported inci- problem worldwide and its prevalence is rapidly increasing. A key dence rates are 10- to 100-fold more than the incidence in the challenge in the treatment of both locally advanced and metastatic United States. The principle histologic types of esophageal disease is to improve our understanding of the underlying molecular cancer are esophageal squamous cell carcinoma (ESCC) and biology. Herein we discuss the most active chemotherapies and tar- esophageal adenocarcinoma (EAC). The relative frequency of geted agents for esophageal cancer, and explore potential differences histologic subtypes differs greatly by geographical location. in the disease between Eastern and Western countries. Over the last 30 years in Western Europe, North America, and Methods: We reviewed the literature for trials involving chemother- Australia, there has been a dramatic shift in the histological apy and targeted agents in locally advanced and metastatic disease 4,5 subtypes from squamous cell to adenocarcinoma. This has in the last 20 years. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Chemotherapeutic and Targeted Strategies for Locally Advanced and Metastatic Esophageal Cancer

Kelly, Ronan J.
Journal of Thoracic Oncology , Volume 8 (6) – Jun 1, 2013
Download PDF
12 pages

Loading next page...
 
/lp/wolters-kluwer-health/chemotherapeutic-and-targeted-strategies-for-locally-advanced-and-T5EE0Ee4Rp

References (96)

Copyright
Copyright © 2013 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e31828b5172
pmid
23591158
Publisher site
See Article on Publisher Site

Abstract

STATE OF THE ART: CONCISE REVIEW Chemotherapeutic and Targeted Strategies for Locally  Advanced and Metastatic Esophageal Cancer Patrick M. Forde, MD and Ronan J. Kelly, MD, MBA highest incidence of esophageal cancer is in Asia and eastern Introduction: Esophageal cancer represents a major health care and southern Africa. In some areas of China, reported inci- problem worldwide and its prevalence is rapidly increasing. A key dence rates are 10- to 100-fold more than the incidence in the challenge in the treatment of both locally advanced and metastatic United States. The principle histologic types of esophageal disease is to improve our understanding of the underlying molecular cancer are esophageal squamous cell carcinoma (ESCC) and biology. Herein we discuss the most active chemotherapies and tar- esophageal adenocarcinoma (EAC). The relative frequency of geted agents for esophageal cancer, and explore potential differences histologic subtypes differs greatly by geographical location. in the disease between Eastern and Western countries. Over the last 30 years in Western Europe, North America, and Methods: We reviewed the literature for trials involving chemother- Australia, there has been a dramatic shift in the histological apy and targeted agents in locally advanced and metastatic disease 4,5 subtypes from squamous cell to adenocarcinoma. This has in the last 20 years.

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jun 1, 2013

There are no references for this article.